BR112022026105A2 - Compostos, composições farmacêuticas, método para o tratamento ou prevenção de adenocarcinoma pulmonar, uso de compostos e invenção - Google Patents

Compostos, composições farmacêuticas, método para o tratamento ou prevenção de adenocarcinoma pulmonar, uso de compostos e invenção

Info

Publication number
BR112022026105A2
BR112022026105A2 BR112022026105A BR112022026105A BR112022026105A2 BR 112022026105 A2 BR112022026105 A2 BR 112022026105A2 BR 112022026105 A BR112022026105 A BR 112022026105A BR 112022026105 A BR112022026105 A BR 112022026105A BR 112022026105 A2 BR112022026105 A2 BR 112022026105A2
Authority
BR
Brazil
Prior art keywords
compounds
pharmaceutical compositions
prevention
treatment
pulmonary adenocarcinoma
Prior art date
Application number
BR112022026105A
Other languages
English (en)
Inventor
Simon Bell Andrew
Besnard Jérémy
Richard Bradley Anthony
Green Luke
Haap Wolfgang
Kocer Buelent
Kuglstatter Andreas
Lucas Xavier
Mattei Patrizio
Mazunin Dmitry
Riemer Claus
Paul Van Hoorn Willem
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BR112022026105A2 publication Critical patent/BR112022026105A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

COMPOSTOS, COMPOSIÇÕES FARMACÊUTICAS, MÉTODO PARA O TRATAMENTO OU PREVENÇÃO DE ADENOCARCINOMA PULMONAR, USO DE COMPOSTOS E INVENÇÃO. A presente invenção fornece compostos de fórmula (I) em que X1, X2, X3, X4, R1, R1a, R1b, R2?, R2, R3?, R3, R6 e R7 são conforme descritos neste documento, bem como os sais farmaceuticamente aceitáveis dos mesmos. Além disso, a presente invenção refere-se à fabricação dos compostos de fórmula (I), composições farmacêuticas que os compreendem e seu uso como medicamentos.
BR112022026105A 2020-06-22 2021-06-21 Compostos, composições farmacêuticas, método para o tratamento ou prevenção de adenocarcinoma pulmonar, uso de compostos e invenção BR112022026105A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20181363 2020-06-22
PCT/EP2021/066767 WO2021259831A1 (en) 2020-06-22 2021-06-21 Sulfone derivatives

Publications (1)

Publication Number Publication Date
BR112022026105A2 true BR112022026105A2 (pt) 2023-01-17

Family

ID=71120071

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022026105A BR112022026105A2 (pt) 2020-06-22 2021-06-21 Compostos, composições farmacêuticas, método para o tratamento ou prevenção de adenocarcinoma pulmonar, uso de compostos e invenção

Country Status (18)

Country Link
US (1) US20230219953A1 (pt)
EP (1) EP4168392A1 (pt)
JP (1) JP2023531020A (pt)
KR (1) KR20230026479A (pt)
CN (1) CN115916756A (pt)
AR (1) AR122705A1 (pt)
AU (1) AU2021294933A1 (pt)
BR (1) BR112022026105A2 (pt)
CA (1) CA3187145A1 (pt)
CL (1) CL2022003677A1 (pt)
CO (1) CO2023000117A2 (pt)
CR (1) CR20220644A (pt)
IL (1) IL298824A (pt)
MX (1) MX2022016455A (pt)
PE (1) PE20230838A1 (pt)
TW (1) TWI812966B (pt)
WO (1) WO2021259831A1 (pt)
ZA (1) ZA202213430B (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117430596A (zh) * 2022-07-13 2024-01-23 上海海和药物研究开发股份有限公司 二并环类mat2a抑制剂及其用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005323311A1 (en) * 2004-11-23 2006-07-13 Venkateswara Rao Batchu Novel bicyclic heterocyclic compounds, process for their preparation and compositions containing them
RU2011142182A (ru) 2009-03-19 2013-04-27 Медикал Рисерч Каунсил Текнолоджи Соединения
MY159151A (en) 2009-12-04 2016-12-15 Nissan Chemical Ind Ltd 2-pyridone compounds
EP2566858A2 (en) 2010-05-04 2013-03-13 Pfizer Inc. Heterocyclic derivatives as alk inhibitors
BR112012029395A2 (pt) 2010-05-17 2016-07-26 Array Biopharma Inc lactamas piperdinil-substituídas como moduladores de gpr119
US8933116B2 (en) 2011-04-04 2015-01-13 Merck Sharp & Dohme Corp. Gamma secretase inhibitors
SG11201400197YA (en) 2011-08-29 2014-05-29 Ptc Therapeutics Inc Antibacterial compounds and methods for use
US9434743B2 (en) * 2012-03-02 2016-09-06 Takeda Pharmaceutical Company Limited Indazole derivatives
UA111687C2 (uk) 2012-11-08 2016-05-25 Пфайзер Інк. Гетероароматичні сполуки як ліганди допаміну d1
EP3036230A1 (en) 2013-08-22 2016-06-29 F. Hoffmann-La Roche AG Alkynyl alcohols and methods of use
AU2015341913B2 (en) * 2014-11-03 2020-07-16 Iomet Pharma Ltd Pharmaceutical compound
WO2018011628A1 (en) 2016-07-11 2018-01-18 Lifesci Pharmaceuticals, Inc. Therapeutic inhibitory compounds
AU2019395338A1 (en) * 2018-12-10 2021-07-29 Ideaya Biosciences, Inc. 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors

Also Published As

Publication number Publication date
ZA202213430B (en) 2023-08-30
TWI812966B (zh) 2023-08-21
US20230219953A1 (en) 2023-07-13
CR20220644A (es) 2023-02-17
TW202208361A (zh) 2022-03-01
MX2022016455A (es) 2023-02-01
AR122705A1 (es) 2022-09-28
IL298824A (en) 2023-02-01
JP2023531020A (ja) 2023-07-20
CA3187145A1 (en) 2021-12-30
EP4168392A1 (en) 2023-04-26
KR20230026479A (ko) 2023-02-24
PE20230838A1 (es) 2023-05-19
WO2021259831A1 (en) 2021-12-30
CN115916756A (zh) 2023-04-04
CL2022003677A1 (es) 2023-07-28
CO2023000117A2 (es) 2023-04-27
AU2021294933A1 (en) 2023-02-02

Similar Documents

Publication Publication Date Title
BR112022025037A2 (pt) Compostos antivirais para tratar infecções por coronavírus, picornavírus e norovírus
BR112022026080A2 (pt) Composto, composições farmacêuticas, compostos de fórmula i ou ii, método para o tratamento ou prevenção de adenocarcinoma pulmonar, uso de compostos e invenção
CL2023001738A1 (es) Inhibidores de prmt5
BR112021026395A2 (pt) Compostos de 2,3-di-hidroquinazolina como inibidores de nav1.8
BR112018001720A2 (pt) compostos de derivado de 1,3,4-oxadiazol sulfonamida como inibidor de histona desacetilase 6 e a composição farmacêutica que compreende os mesmos
BR112021022659A2 (pt) Compostos triarílicos para o tratamento de doenças pd-l1
BR112015001419A8 (pt) composto, composição farmacêutica, e, uso de um composto ou de um sal farmaceuticamente aceitável do mesmo
BR112018068565A2 (pt) combinações de inibidores de lsd1 para uso no tratamento de tumores sólidos
BR112016015983A2 (pt) Compostos de indazol como inibidores de irak4, seus usos, e composição farmacêutica
BR112018071216A2 (pt) inibidores de bromodomínios
BR0212378A (pt) Inibidores de 17beta-hidroxiesteróide desidrogenase tipo 3 para o tratamento de doenças dependentes de androgênio
BR112022000019A2 (pt) Composto da fórmula, composição farmacêutica e método de tratamento de câncer
CO2023007504A2 (es) Derivados de carboxamida tricíclica como inhibidores de prmt5
NI201900088A (es) Dendrímeros terapéuticos
BR112022006018A2 (pt) Heteroaril-bifenil amidas para o tratamento de doenças relacionadas à pd-l1
BR112023022580A2 (pt) Inibidores alostéricos de cromenona de fosfoinositídeo 3-quinase (pi3k) para o tratamento de doenças
BR112019004248A2 (pt) inibidores da dopamina-b-hidroxilase
BR112022006279A2 (pt) Heteroaril-bifenil aminas para o tratamento de doenças pd-l1
BR112022021962A2 (pt) Imidazopiridazinas como moduladores de il-17
BR112019024322A2 (pt) Compostos e composições terapêuticos e métodos de uso dos mesmos
CL2021001388A1 (es) Compuestos útiles en la terapia para el vih
BR112021023770A2 (pt) Compostos de derivado de 1,3,4-oxadiazol como inibidor de histona desacetilase 6 e a composição farmacêutica que compreende os mesmos
BR112021017604A2 (pt) Compostos úteis na terapia para hiv
BR112023022890A2 (pt) Inibidores de cromenona alostéricos de fosfoinositídio 3-cinase (pi3k), composições farmacêuticas que os compreendem e usos dos mesmos
BR112022000782A2 (pt) Composto, composição farmacêutica, processo para preparar um composto, composto intermediário, e, uso de um composto, ou de um sal farmaceuticamente aceitável ou solvato do mesmo, ou de uma composição farmacêutica